Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • SeQuent's arm Alivira...

    SeQuent's arm Alivira gets USFDA nod for Visakhapatnam API facility

    Written by Ruby Khatun Khatun Published On 2017-05-03T11:53:00+05:30  |  Updated On 3 May 2017 11:53 AM IST
    SeQuents arm Alivira gets USFDA nod for Visakhapatnam API facility
    New Delhi: Drug firm SeQuent Scientific said its arm Alivira has received approval from the US health regulator for its animal health API facility in Visakhapatnam in Andhra Pradesh.

    Alivira has received United States Food and Drug Administration (USFDA) approval for its multi-product animal health active pharmaceutical ingredient (API) facility in Visakhapatnam, SeQuent Scientific said in a filing to the BSE.

    The facility was inspected for the first time by the USFDA in November 2016 and has now received Establishment Inspection Report (EIR) from the regulator, it added.

    The receipt of the EIR will enable Alivira's entry into USD 8 billion veterinary healthcare market in the US, SeQuent Scientific said.

    "We are pleased with the USFDA approval for our animal health API facility, which is a critical milestone in our journey to build a global animal health business out of India," Alivira MD Manish Gupta said.

    While the company is already working with most of the leading animal health companies the world over, this approval will enable it to expand its reach and consolidate relationship with these enterprises, he added.

    Alivira Animal Health Ltd is a wholly-owned subsidiary of SeQuent Scientific. It has six manufacturing facilities.

    The stock of SeQuent Scientific today closed at Rs 125.50 on the BSE, up 0.56 per cent.
    Active Pharmaceutical IngredientAliviraAndhra PradeshAPI facilityapprovalManish GuptaSeQuent ScientificUnited States Food and Drug AdministrationUSFDAveterinary healthcareVisakhapatnam
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok